How does precision medicine actually help with rare diseases?
Precision medicine tailors treatment to a patient's unique genetic and molecular profile, which is critical for rare diseases where standard approaches often fail. The core challenge is that over 90% of rare diseases lack any approved therapy [1]. Precision medicine tackles this by using tools like knowledge graphs—networks that connect genomic data, clinical history, and drug information—to find hidden links between a patient's genetic mutation and an existing drug that might work [2][4]. For instance, the AI tool mediKanren has been used to help over 500 rare disease families by scanning vast biomedical databases to suggest drug repurposing opportunities [4].
In blood cancers (hematological malignancies), precision medicine is more advanced. Genetic testing has been used for decades to classify subtypes and guide treatment, leading to clear survival benefits with targeted drugs like BCR::ABL1 inhibitors for certain leukemias [5]. This shows that when the genetic driver is known and a drug exists, precision medicine can deliver real results.
Does the evidence show that precision medicine actually improves outcomes?
The strongest evidence comes from hematological malignancies, where precision diagnostics have directly improved survival by matching patients to targeted therapies [5]. This is a best-case scenario: a well-understood genetic alteration and a drug designed to hit it. For the broader landscape of rare diseases, the evidence is more about potential than proven outcomes. The mediKanren tool has been applied to over 500 families, but the abstract does not specify how many of those cases led to a successful treatment [4]. Similarly, AI-driven drug discovery is accelerating the identification of new targets and repurposing candidates, but most of these are still in early stages [1].
A key insight from the research is that rare diseases and precision medicine need each other: studying rare genetic cases often reveals mechanisms that apply to common diseases, and vice versa [6]. This means that even when direct outcome data is thin for a specific rare disease, the knowledge gained from precision medicine approaches can build a foundation for future treatments. However, the gap between best-case (blood cancers) and typical-case (most rare diseases) is large, and readers should not expect immediate cures for every condition.
What are the limitations? When doesn't it work well?
Precision medicine for rare diseases faces several hurdles. First, data is scarce: with only a few patients per disease, it's hard to build robust models or run clinical trials [1][2]. Second, the tools are still maturing—AI models can suggest treatments, but they require high-quality genomic and clinical data, which isn't always available [3]. Third, even when a potential drug is identified, it may not be tested in that rare disease, so the outcome is uncertain [4].
Ethical concerns also arise: integrating AI and genetic data raises privacy issues and risks of algorithmic bias, which could worsen disparities if not carefully managed [3]. Finally, the economic incentive is weak—developing treatments for very small patient populations is costly, which is why over 90% of rare diseases still lack therapies [1]. So while precision medicine offers hope, it is not a magic bullet, and progress will be uneven across different diseases.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2022 to 2024, 3 from 2024 or later, 4 in Q1 journals, collectively cited 144 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 44 papers retrieved from a database of over 500 million.
Sources used in this answer
AI-Driven Drug Discovery for Rare Diseases
This review highlights that over 90% of rare diseases lack effective therapies, and argues that AI-driven drug discovery (including repurposing and biomarker identification) can accelerate treatment development, though most applications are still in early stages.
Leveraging Knowledge Graphs for Enhanced Medical Reasoning in Personalized Medicine for Rare Diseases
This project proposes using knowledge graphs to integrate genomic, clinical, and pharmacological data for rare disease diagnosis and treatment, with expected improvements in diagnostic accuracy and personalized treatment pathways, but no quantitative outcome data is reported.
Harnessing the Power of Precision Medicine and AI
This chapter discusses the potential of precision medicine and AI to improve outcomes in rare diseases, but also emphasizes ethical challenges like data privacy and algorithmic bias, without providing specific outcome data.
The precision medicine process for treating rare disease using the artificial intelligence tool mediKanren
The mediKanren AI tool, which uses knowledge graphs to link genetic insights to drug repurposing opportunities, has been applied to over 500 rare disease families, demonstrating a scalable process for identifying potential treatments.
Novel precision medicine approaches and treatment strategies in hematological malignancies
In hematological malignancies, precision diagnostics using genetic testing (e.g., for BCR::ABL1) have directly improved survival by guiding targeted therapy, representing one of the strongest evidence bases for precision medicine in rare diseases.
Why rare disease needs precision medicine—and precision medicine needs rare disease
This perspective argues that rare disease research is essential for precision medicine because rare genetic cases reveal mechanisms applicable to common diseases, and vice versa, creating a symbiotic relationship.